Therapeutic Drug Monitoring in Children and Adolescents: Findings on Fluoxetine from the TDM-VIGIL Trial

• Príomhchruthaitheoirí: Michael Frey (Údar), Lukasz Smigielski (Údar), Elvira Tini (Údar), Stefanie Fekete (Údar), Christian Fleischhaker (Údar), Christoph Wewetzer (Údar), Andreas Karwautz (Údar), Christoph U. Correll (Údar), Manfred Gerlach (Údar), Regina Taurines (Údar), Paul L. Plener (Údar), Uwe Malzahn (Údar), Selina Kornbichler (Údar), Laura Weninger (Údar), Matthias Brockhaus (Údar), Su-Yin (Údar), Karl Reitzle (Údar), Hans Rock (Údar), Hartmut Imgart (Údar), Peter Heuschmann (Údar), Stefan Unterecker (Údar), Wolfgang Briegel (Údar), Tobias Banaschewski (Údar), Jörg M. Fegert (Údar), Tobias Hellenschmidt (Údar), Michael Kaess (Údar), Michael Kölch (Údar), Tobias Renner (Údar), Christian Rexroth (Údar), Susanne Walitza (Údar), Gerd Schulte-Körne (Údar), Marcel Romanos (Údar), Karin Maria Egberts (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: MDPI AG, 2023-08-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Fluoxetine is the recommended first-line antidepressant in many therapeutic guidelines for children and adolescents. However, little is known about the relationships between drug dose and serum level as well as the therapeutic serum reference range in this age group. Within a large naturalistic obse...